-
REAL WORLD SURVIVAL OUTCOMES FOLLOWING REIMBURSED ANTI-PD-1 IMMUNOTHERAPY FOR MELANOMA IN IRELAND A POPULATION-BASED NATIONAL CANCER REGISTRY STUDY
Aug 11, 2026, 17:16 PM -
HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH PEDIATRIC PNEUMOCOCCAL DISEASE HOSPITALIZATIONS IN SPAIN: RESULTS FROM THE NATIONAL HOSPITAL DISCHARGE DATABASE
Aug 11, 2026, 17:16 PM -
UNDERSTANDING THE ECONOMIC IMPACT OF SURGICAL TREATMENT PATHWAYS IN RECTAL CANCER
Aug 11, 2026, 17:16 PM -
COST-UTILITY ANALYSIS OF OBINUTUZUMAB BETA VERSUS INEBILIZUMAB AND SATRALIZUMAB FOR NEUROMYELITIS OPTICA SPECTRUM DISORDER IN CHINA
Aug 11, 2026, 17:16 PM -
EVALUATING THE COST-OFFSETS OF COMMUNITY MEASLES VACCINATION COVERAGE USING A STOCHASTIC SEIR MODEL
Aug 11, 2026, 17:16 PM -
MEDICATION COST SAVINGS AND COST AVOIDANCE FROM CLINICAL PHARMACIST-LED INTRAVENOUS-TO-ORAL CONVERSION IN POSTOPERATIVE SURGICAL PATIENTS AT A TERTIARY CANCER CENTRE IN A LOWER-MIDDLE-INCOME COUNTRY
Aug 11, 2026, 17:16 PM -
THE HIDDEN PATIENT BURDEN IN ALOPECIA AREATA AND VITILIGO: IDENTIFYING GAPS IN ROUTINE DATA CAPTURE
Aug 11, 2026, 17:16 PM -
ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF DELAYED SOTATERCEPT INITIATION AS ADD-ON TO BACKGROUND THERAPY IN ADULT PATIENTS WITH SYMPTOMATIC PULMONARY ARTERIAL HYPERTENSION IN ITALY
Aug 11, 2026, 17:16 PM -
CASE DETERMINATION IN WILSON'S DISEASE: A POPULATION-BASED STUDY OF MORTALITY AND LONG-TERM OUTCOME IN THE FRENCH NATIONAL INSURANCE CLAIMS
Aug 11, 2026, 17:16 PM -
POPULATION CHARACTERISTICS, HEALTHCARE RESOURCE USE AND COSTS OF HIDRADENTIS SUPPURATIVA IN FRANCE - THE HESTIA STUDY
Aug 11, 2026, 17:16 PM -
PATIENT AND CAREGIVER EXPERIENCES OF PANCREATIC CANCER AND PERSPECTIVES ON EARLY DETECTION STRATEGIES IN GREECE: QUALITATIVE FINDINGS FROM THE SHIELD EU PROJECT
Aug 11, 2026, 17:16 PM -
FEASIBILITY OF INDIRECT TREATMENT COMPARISONS IN RELAPSED POLYMYALGIA RHEUMATICA
Aug 11, 2026, 17:16 PM -
DOMINATING RSV: COST-EFFECTIVENESS OF CLESROVIMAB IN INFANTS BORN TO UNVACCINATED MOTHERS IN ARGENTINA
Aug 11, 2026, 17:16 PM -
HAVE NICE'S INCREASED COST-EFFECTIVENESS THRESHOLDS IMPROVED TECHNOLOGY APPRAISAL OUTCOMES?
Aug 11, 2026, 17:16 PM -
TRENDS IN 12-MONTH MORTALITY AND STATUTORY HEALTH INSURANCE COSTS IN INCIDENT METASTATIC BLADDER CANCER IN GERMANY, 2011-2024
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS OF EARLY VERSUS DELAYED CAR-T STRATEGIES FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA IN SOUTH KOREA
Aug 11, 2026, 17:16 PM -
A FEASIBILITY ASSESSMENT OF AN ANCHORED INDIRECT TREATMENT COMPARISON BETWEEN ENEBOPARATIDE (CALYPSO) AND PALOPEGTERIPARATIDE (PATHWAY) IN CHRONIC HYPOPARATHYROIDISM
Aug 11, 2026, 17:16 PM -
PATIENT PARTICIPATION IN HEALTH TECHNOLOGY ASSESSMENT: A PROPOSAL FOR METHODOLOGICAL FRAMEWORK BASED ON SATURATION-BASED REGISTRY AND CAUSAL INFERENCE METHOD
Aug 11, 2026, 17:16 PM -
TIME TOXICITY IN CANCER CARE AND TIME SPENT IN HEALTHCARE ACROSS CANCER AND TREATMENT TYPES IN FINLAND
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF DEPREXIS, A PRESCRIBED DIGITAL THERAPEUTIC INTERVENTION FOR UNTREATED ADULTS WITH MAJOR DEPRESSIVE DISORDER IN SOUTH AFRICA
Aug 11, 2026, 17:16 PM
